Advertisement

International Journal of Hematology

, Volume 107, Issue 6, pp 712–715 | Cite as

Successful treatment of follicular lymphoma with second-generation tyrosine kinase inhibitors administered for coexisting chronic myeloid leukemia

  • Shin-ichiro Fujiwara
  • Yuya Shirato
  • Takashi Ikeda
  • Shin-ichiro Kawaguchi
  • Yumiko Toda
  • Shoko Ito
  • Shin-ichi Ochi
  • Takashi Nagayama
  • Kiyomi Mashima
  • Kento Umino
  • Daisuke Minakata
  • Hirofumi Nakano
  • Kaoru Morita
  • Ryoko Yamasaki
  • Yasufumi Kawasaki
  • Miyuki Sugimoto
  • Masahiro Ashizawa
  • Chihiro Yamamoto
  • Kaoru Hatano
  • Kazuya Sato
  • Iekuni Oh
  • Ken Ohmine
  • Kazuo Muroi
  • Yoshinobu Kanda
Case Report

Abstract

Tyrosine kinase inhibitors (TKIs) are standard therapy for chronic myeloid leukemia (CML). However, the effects of these agents on mature B cell lymphoma are not well known. We describe a 50-year-old man who was diagnosed with CML in the chronic phase and treated with imatinib. After 3 years of imatinib therapy that achieved a complete cytogenetic response of CML, he developed Philadelphia-negative follicular lymphoma (FL). Rituximab monotherapy induced a partial response of FL, and he subsequently achieved a major molecular response (MMR) of CML. Three years later, however, the MMR was lost, followed by the progression of FL. Imatinib was switched to nilotinib for the treatment of CML, while we chose watchful waiting for FL. He achieved MMR again under treatment with nilotinib for 8 months including one month of substitutional use of dasatinib due to adverse events, but thereafter nilotinib was switched to bosutinib due to hyperbilirubinemia. With the administration of second-generation TKIs (2G-TKIs) for a total of 18 months, he achieved a complete response to FL without antilymphoma treatment. This is the first report to suggest that 2G-TKIs may have direct or indirect effects on FL.

Keywords

CML FL Second-generation TKI 

Notes

Compliance with ethical standards

Conflict of interest

Dr. Kanda has received grants and personal fees from Pfizer and personal fees from Novartis. The other authors have nothing to disclose.

References

  1. 1.
    O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994–1004.CrossRefPubMedGoogle Scholar
  2. 2.
    Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362:2260–70.CrossRefPubMedGoogle Scholar
  4. 4.
    Kitagawa D, Yokota K, Gouda M, Narumi Y, Ohmoto H, Nishiwaki E, et al. Activity-based kinase profiling of approved tyrosine kinase inhibitors. Genes Cells. 2013;18:110–22.CrossRefPubMedGoogle Scholar
  5. 5.
    Amrein PC, Attar EC, Takvorian T, Hochberg EP, Ballen KK, Leahy KM, et al. Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res. 2011;17:2977–86.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Kater AP, Spiering M, Liu RD, Doreen Te Raa G, Slinger E, Tonino SH, et al. Dasatinib in combination with fludarabine in patients with refractory chronic lymphocytic leukemia: a multicenter phase 2 study. Leuk Res. 2014;38:34–41.CrossRefPubMedGoogle Scholar
  7. 7.
    Hebb J, Assouline S, Rousseau C, Desjardins P, Caplan S, Egorin MJ, et al. A phase I study of imatinib mesylate in combination with chlorambucil in previously treated chronic lymphocytic leukemia patients. Cancer Chemother Pharmacol. 2011;68:643–51.CrossRefPubMedGoogle Scholar
  8. 8.
    Wildes TM, Procknow E, Gao F, Dipersio JF, Vij R. Dasatinib in relapsed or plateau-phase multiple myeloma. Leuk Lymphoma. 2009;50:137–40.CrossRefPubMedGoogle Scholar
  9. 9.
    Krysiak K, Gomez F, White BS, Matlock M, Miller CA, Trani L, et al. Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma. Blood. 2017;129:473–83.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31:88–94.CrossRefPubMedGoogle Scholar
  11. 11.
    Ujjani CS, Jung SH, Pitcher B, Martin P, Park SI, Blum KA, et al. Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103. Blood. 2016;128:2510–6.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    de Lavallade H, Khoder A, Hart M, Sarvaria A, Sekine T, Alsuliman A, et al. Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling. Blood. 2013;122:227–38.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Remsing Rix LL, Rix U, Colinge J, Hantschel O, Bennett KL, Stranzl T, et al. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia. 2009;23:477–85.CrossRefPubMedGoogle Scholar
  14. 14.
    Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010;115:2578–85.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Hantschel O, Rix U, Superti-Furga G. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk Lymphoma. 2008;49:615–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Epling-Burnette PK, Guilhot F, et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia. 2009;23:1398–405.CrossRefPubMedGoogle Scholar
  17. 17.
    Hughes A, Clarson J, Tang C, Vidovic L, White DL, Hughes TP, et al. CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors. Blood. 2017;129:1166–76.CrossRefPubMedGoogle Scholar
  18. 18.
    Miranda MB, Lauseker M, Kraus MP, Proetel U, Hanfstein B, Fabarius A, et al. Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV. Leukemia. 2016;30:1255–62.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Drobyski WR, Qazi R. Spontaneous regression in non-Hodgkin’s lymphoma: clinical and pathogenetic considerations. Am J Hematol. 1989;31:138–41.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2017

Authors and Affiliations

  • Shin-ichiro Fujiwara
    • 1
  • Yuya Shirato
    • 1
  • Takashi Ikeda
    • 1
  • Shin-ichiro Kawaguchi
    • 1
  • Yumiko Toda
    • 1
  • Shoko Ito
    • 1
  • Shin-ichi Ochi
    • 1
  • Takashi Nagayama
    • 1
  • Kiyomi Mashima
    • 1
  • Kento Umino
    • 1
  • Daisuke Minakata
    • 1
  • Hirofumi Nakano
    • 1
  • Kaoru Morita
    • 1
  • Ryoko Yamasaki
    • 1
  • Yasufumi Kawasaki
    • 1
  • Miyuki Sugimoto
    • 1
  • Masahiro Ashizawa
    • 1
  • Chihiro Yamamoto
    • 1
  • Kaoru Hatano
    • 1
  • Kazuya Sato
    • 1
  • Iekuni Oh
    • 1
  • Ken Ohmine
    • 1
  • Kazuo Muroi
    • 1
  • Yoshinobu Kanda
    • 1
  1. 1.Division of Hematology, Department of MedicineJichi Medical UniversityShimotsukeJapan

Personalised recommendations